China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its dexmedetomidine hydrochloride nasal spray (1ml:500μg). The drug is approved for use as a preoperative sedation in adults.
History and Innovation of Dexmedetomidine
Dexmedetomidine was first applied in clinical settings in the US in 1999. Hengrui Pharmaceuticals introduced the first injectable version of the drug in China, receiving marketing approval in 2009. The company’s latest product, awarded priority review status in China in September 2022, is the first nasal spray dosage form of dexmedetomidine globally. This innovation marks a significant advancement in the administration and convenience of preoperative sedation.-Fineline Info & Tech
